Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Zhejiang Huahai and Breckenridge Sign Agreement for Generic HIV Drug

publication date: May 8, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Zhejiang Huahai Pharmaceutical and Breckenridge Pharmaceutical have signed an exclusive marketing and distribution agreement for Huahai’s HIV drug Nevirapine. Breckenridge will market Nevirapine, a generic version of Boehringer Ingelheim’s antiviral HIV drug, Viramune®, in the US after BI’s patent on Viramune expires on May 22, 2012. Deal terms were not disclosed. More details…

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners